Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Return on Assets (2017 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Return on Assets for 9 consecutive years, with 0.4% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Assets rose 29.0% to 0.4% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.4%, a 29.0% increase, with the full-year FY2025 number at 0.45%, up 27.0% from a year prior.
  • Return on Assets was 0.4% for Q4 2025 at Rhythm Pharmaceuticals, up from 0.44% in the prior quarter.
  • In the past five years, Return on Assets ranged from a high of 0.39% in Q2 2021 to a low of 0.93% in Q1 2024.
  • A 5-year average of 0.55% and a median of 0.53% in 2021 define the central range for Return on Assets.
  • Peak YoY movement for Return on Assets: plummeted -43bps in 2024, then skyrocketed 49bps in 2025.
  • Rhythm Pharmaceuticals' Return on Assets stood at 0.52% in 2021, then rose by 10bps to 0.47% in 2022, then dropped by -15bps to 0.54% in 2023, then fell by -28bps to 0.69% in 2024, then skyrocketed by 42bps to 0.4% in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Return on Assets are 0.4% (Q4 2025), 0.44% (Q3 2025), and 0.48% (Q2 2025).